Filing Flows › Silence Therapeutics (SLN) › R&D spending
Silence Therapeutics (SLN) R&D spending by quarter
Silence Therapeutics' R&D spending was $9.1M in Q1 2026 (first quarter 2026), +4% from Q4 2025. Over the last 6 quarters it ranged from $8.7M (Q4 2025) to $22.1M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $9.1M | +4% | -56% |
| Q4 2025 | $8.7M | -57% | -60% |
| Q3 2025 | $20.5M | +16% | — |
| Q2 2025 | $17.6M | -15% | — |
| Q1 2025 | $20.8M | -6% | — |
| Q4 2024 | $22.1M | — | — |
Q1 2026 at a glance
Silence Therapeutics, Q1 2026: revenue $422K (+197% year over year), net loss $15.0M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Silence Therapeutics' R&D spending?
Silence Therapeutics' R&D spending was $9.1M in Q1 2026 (first quarter 2026), +4% from Q4 2025.
How has Silence Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $8.7M (Q4 2025) to $22.1M (Q4 2024).